ACG 2024

View the newest and most insightful research on gastrointestinal diseases from ACG 2024, which took place October 25-30, 2024, in Philadelphia, PA.

Inconsistent Definitions of Moderate IBD Across Phase 3 Pharmacologic Trials
Inconsistent Definitions of Moderate IBD Across Phase 3 Pharmacologic Trials
Jordana JampelGastroenterology | November 12, 2024
Definitions and stratifications comprised the name of measurement index and the score or range of scores used.
Upadacitinib is Effective in Hospitalized Patients With Crohn Disease
Upadacitinib is Effective in Hospitalized Patients With Crohn Disease
Rob DillardACG 2024 | November 4, 2024
Upadacitinib (Rinvoq) therapy yields favorable outcomes in people with Crohn disease (CD).
Assessing the Risk of MI, Stroke, Thromboembolic Events in Patients With UC Treated With Tofacitinib, Biologics
Assessing the Risk of MI, Stroke, Thromboembolic Events in Patients With UC Treated With Tofacitinib, Biologics
Rob DillardACG 2024 | October 30, 2024
Patients with ulcerative colitis taking tofacitinib or biologics do not have an increased risk of MI or stroke.
Adalimumab Biosimilars as Effective as Origin Formula in Patients With IBD
Adalimumab Biosimilars as Effective as Origin Formula in Patients With IBD
Jordana JampelACG 2024 | October 29, 2024
The biosimilars were as effective in treating inflammatory bowel disease.
Advertisement
Advertisement
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Contribute

    Contact Us

    Our Network

    MashupMD

    Blood Cancers Today

    Cancer Nursing Today

    GU Oncology Now

    Urban Health Today

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |